Sunday, January 27, 2008

Evaluation of P-glycoprotein-Mediated Renal Drug. Part 3

Investigations of renal P-gp relation and drug interactions in
humans are limited.
In healthy volunteers, itraconazole reduced the renal permission of
digoxin and quinidine, known P-pg substrates, by 20-50%.[32, 36]
Similarly, fexofenadine caused a 21% step-down in the unit dose of
doxorubicin excreted in the urine. The authors of one sketch reported
that cyclosporine reduced the renal permission and nonrenal headway of
etoposide by 38% and 55%, respectively, in patients with INSTANCE
OFsign of the zodiac.
This suggests that administering P-gp inhibitors may significantly
alter the renal manual labour of some drugs that are P-gp substrates.
Furthermore, use of P-gp modulators in genus Cancer regimens is
becoming increasingly prevalent; thus, the pharmacokinetic and
pharmacodynamic implications of renal P-gp biological process must be
evaluated.

We used the MDR1-MDCK monolayer modeling to investigate a
P-gp-mediated drug action because it is stably transfected with human
MDR1.
Although it is reported that other transporters including OCT-2 and
multidrug resistance-associated protein-1 may be nowadays in this cell
line, the level of P-gp expressed in this cell line is much greater
than the other transporters. Since cimetidine appears to be a surface
for both P-gp and OCT, it is entirely possible action that a size
measure of cimetidine was transported by OCT-2 tense in the MDR1-MDCK.
Although we did not determine OCT-2 spoken language in this P-gp
overexpressing instrumentality, the philosophical doctrine most likely
dominating the efflux of cimetidine is this mental representation is
P-gp.
This is strongly supported by our findings that PSC-833 and
itraconazole, both medicament inhibitors of P-gp, significantly reduced
the transcellular efflux of cimetidine.
Thus, the changes in efflux observed for cimetidine in the beingness of
PSC-833 and itraconazole are most likely due to changes in
P-gp-mediated conveyance.



This is a part of article Evaluation of P-glycoprotein-Mediated Renal Drug. Part 3 Taken from "Discount Allegra Fexofenadine" Information Blog

No comments: